Erratum: Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis - Correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met(Tumor Biology DOI: 10.1007/s13277-013-0776-1);Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis - Correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met

Tumor Biology

Volumn 34, Issue 4, 2013, Pages 2109-2117

  Garouniatis, Alexandros ^a   Zizi Sermpetzoglou, Adamantia ^b   Rizos, Spyros ^b   Kostakis, Alkiviadis ^c   Nikiteas, Nikolaos ^c   Papavassiliou, Athanasios G ^c  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Caveolin 1; Colorectal cancer (CRC); VEGFR 1; VEGFR 3

Indexed keywords

CAVEOLIN 1; CD44V6 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOLECULAR INTERACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEX DIFFERENCE; TUMOR LOCALIZATION;

EID: 84881479125     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0918-5     Document Type: Erratum

References (40)

1. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70.
2. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
3. Svendsen MN, Lykke J, Werther K, Christensen IJ, Nielsen HJ. Concentrations of VEGF and VEGFR1 in paired tumor arteries and veins in patients with rectal cancer. Oncol Res. 2004;14:611-5.
4. MyÅliwiec P, Piotrowski Z, Zalewski B, Kukliński A, Pawlak K. Plasma VEGF-A and its soluble receptor R1 correlate with the clinical stage of colorectal cancer. Rocz Akad Med Bialymst. 2004;49:85-7.
5. Lesslie DP, Summy JM, Parikh NU, Fan F, Trevino JG, Sawyer TK, et al. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer. 2006;94:1710-7.
6. Yamaguchi T, Bando H, Mori T, Takahashi K, Matsumoto H, Yasutome M, et al. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis. Cancer Sci. 2007;98:405-10.
7. Yang SH, Lin JK, Huang CJ, Chen WS, Li SY, Chiu JH. Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation. J Surg Res. 2005;128:140-6.
8. Kong HL, Hecht D, Song W, Kovesdi I, Hackett NR, Yayon A, et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther. 1998;9:823-33.
9. Roda JM, Wang Y, Sumner LA, Phillips GS, Marsh CB, Eubank TD. Stabilization of HIF-2alpha induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol. 2012;189:3168-77.
10. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92:3566-70.
11. Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol. 2000;156:1499-504.
12. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science. 1998;282:946-9.
13. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol. 1997;33:369-74.
14. Yonemura Y, Endo Y, Tabata K, Kawamura T, Yun HY, Bandou E, et al. Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer. Int J Clin Oncol. 2005;10:318-27.
15. Schneider M, Büchler P, Giese N, Giese T, Wilting J, Büchler MW, et al. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. Int J Oncol. 2006;28:883-90.
16. Valtola R, Salven P, Heikkilä P, Taipale J, Joensuu H, Rehn M, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999;154:1381-90.
17. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, et al. Lymphatic metastasis in the absence of functional intratumour lymphatics. Science. 2002;296:1883-6.
18. Williams TM, Lisanti MP. The caveolin proteins. Genome Biol. 2004;5:214.
19. Ha TK, Chi SG. CAV1/caveolin 1 enhances aerobic glycolysis in colon cancer cells via activation of SLC2A3/GLUT3 transcription. Autophagy. 2012;8:1684-5.
20. Shatz M, Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer. Int J Radiat Biol. 2008;84:177-89.
21. Selga E, Morales C, Noé V, Peinado MA, Ciudad CJ. Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Med Genet. 2008;1:35.
22. Nimri L, Barak H, Graeve L, Schwartz B. Restoration of caveolin-1 expression suppresses growth, membrane-type-4 metalloproteinase expression and metastasis-associated activities in colon cancer cells. Mol Carcinog. 2012. doi: 10.1002/mc.21927.
23. Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology. 2006;131:797-808.
24. Cantiani L, Manara MC, Zucchini C, De Sanctis P, Zuntini M, Valvassori L, et al. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res. 2007;67:7675-85.
25. Basu Roy UK, Henkhaus RS, Loupakis F, Cremolini C, Gerner EW, Ignatenko NA. Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis. Int J Cancer. 2012. doi: 10.1002/ijc.28001.
26. Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis. 2013;28:9-18.
27. Kim JY, Bae BN, Kwon JE, Kim HJ, Park K. Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma. APMIS. 2011;119:449-59.
28. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, Lisanti MP. Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci U S A. 1996;93:131-5.
29. Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, et al. Quantitative expression of VEGF, VEGF-R1, VEGF-R2 and VEGF-R3 in melanoma tissue microarrays. Hum Pathol. 2010;41:375-84.
30. Fine SW, Lisanti MP, Galbiati F, Li M. Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol. 2001;115:719-24.
31. Simiantonaki N, Taxeidis M, Jayasinghe C, Kirkpatrick CJ. Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status. Anticancer Res. 2007;27:3245-50.
32. Okita NT, Yamada Y, Takahari D, Hirashima Y, Matsubara J, Kato K, et al. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer. Jpn J Clin Oncol. 2009;39:595-600.
33. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol. 2003;200:183-94.
34. Jayasinghe C, Simiantonaki N, Michel-Schmidt R, Kirkpatrick CJ. Endothelial VEGFR-3 expression in colorectal carcinomas is associated with hematogenous metastasis. Oncol Rep. 2009;22:1093-100.
35. Alam A, Blanc I, Gueguen-Dorbes G, Duclos O, Bonnin J, Barron P, et al. SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities. Mol Cancer Ther. 2012;11:1637-49.
36. Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P, et al. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol. 2003;13:1721-7.
37. Quest AFG, Torres VA, Rodriguez DA, Gutierrez-Pajares J, Tapia JC. Caveolin-1 in colon cancer: the flexible connection to Wnt signaling. In: Mercier I, Jasmin J-F, Lisanti MPP, editors. Caveolins in cancer pathogenesis, prevention and therapy. New York: Springer; 2012. p. 17-41.
38. Soreide K, Berg M, Skudal BS, Nedreboe BS. Advances in the understanding and treatment of colorectal cancer. Discov Med. 2011;12:393-404.
39. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem. 1997;272:30429-38.
40. Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, Griffith OL, et al. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res. 2008;68:8210-20.